stockrowScholar Rock Holding Corporation
SRRK Healthcare Biotechnology
Scholar Rock Holding Corporation’s revenue for fiscal 2022 (year ended December 2022) was $33.2 million.
- EPS
- +14.3%
- Free cash flow
- +8.88%
- Total debt
- +294.3%
Quarter to June 2026, against a year earlier
Follow SRRK
Alert me
Scholar Rock Holding Corporation (SRRK) EV/Sales
As of 6 November 2026, Scholar Rock Holding Corporation (SRRK) trades at a EV/Sales of 123×. Over the past ten years it has ranged from −2.3× (July 2022) to 160× (August 2026); the current reading is higher than 96% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2022 | 6.5× | (82.82%) |
| FY2021 | 37.6× | (50.73%) |
| FY2020 | 76.3× | 645.66% |
| FY2019 | 10.2× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2022 | 6.7× | (82.22%) |
| Dec 2021 | 37.6× | (30.86%) |
| Sep 2021 | 54.4× | 7.24% |
| Jun 2021 | 50.7× | (50.77%) |
| 9 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BLTE Belite Bio, Inc. Sponsored ADR compare | n/m |
| ERAS Erasca, Inc. compare | n/m |
| MANE Veradermics Incorporated compare | n/m |
| IMVT Immunovant, Inc. compare | n/m |
| KOD Kodiak Sciences Inc. compare | n/m |
| PTCT PTC Therapeutics, Inc. compare | 5.4× |
| SRRK Scholar Rock Holding Corporation | 120× |
| COGT Cogent Biosciences, Inc. compare | 195× |
| CGON CG Oncology, Inc. compare | 755× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on SRRK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- The full statement